To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to promulgate rules to update certain regulations relating to human cells, tissues, and cellular and tissue-based products, and for other purposes.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 7, 2022)
This bill requires the Food and Drug Administration to update its regulations relating to the manufacture of human cells, tissue, and cellular and tissue-based products (HCT/Ps), including an update to the definition of minimal manipulation. (The regulations are commonly referred to as the tissue rules; HCT/Ps that are minimally manipulated and meet other criteria are not regulated as drugs, devices, or biologics and therefore are not subject to premarket review.)
What just happenedMar 8, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 7, 2022
- Mar 8, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 7, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 7, 2022IntroReferralIntro-H
Introduced in House
- Mar 7, 2022IntroReferral1000
Introduced in House